Ofatumumab, Multiple Sclerosis Drug Candidate, Shows Promise In Phase 2 Study
"We are encouraged by the results from this study," Genmab's chief executive Jan van de Winkel said in the statement. There
ofatumumab multiple sclerosis drug candidate show promise phase study encourage result study genmab chief executive jan van de winkel say statement